Recent Updates
Recently added Catalysts

GSK Bio's influenza vaccine GSK2186877A

Phase 3

Influenza | Monoclonal antibody | Infectious Disease |GSK plc|Last Updated: Aug 17, 2018

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindACTIVE_CONTROLLED
Total Trials2
Total Enrollment44,221
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00760617Evaluation of Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Years and OlderPHASE3 COMPLETED 526Oct 6, 2008May 15, 2009Aug 17, 201825 Germany, Netherlands +1
NCT00753272Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and OlderPHASE3 COMPLETED 43,695Sep 15, 2008Jan 5, 2011Jun 8, 2018274 United States, Belgium +13
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)
Day 0-6

Grade 3 ecchymosis, redness and swelling was greater than or equal to 100 millimeter (mm) i.e. ≥ 100 mm and grade 3 pain was considerable pain at rest, that prevented normal everyday activities. Any was occurrence of any local symptom regardless of their intensity grade.

Duration of Solicited Local AEs
Day 0-6

Duration was defined as number of days with any grade of local symptoms and grade for quantifiable symptoms: ecchymosis, redness and swelling was greater than (\>) 20mm.

Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs
Day 0-6

Any fever was defined as oral temperature ≥38.0 degree centigrade (°C), grade 3 fever was oral temperature \>40.0°C. For other symptoms, any was defined as occurrence of any general symptom regardless of intensity grade or relationship to vaccination, grade 3 was defined as a general symptom that prevented normal activity and related was a general symptom assessed by the investigator as causally related to the study vaccination.

Duration of Solicited General AEs
Day 0-6

Duration was defined as number of days with any grade of general symptoms.

Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs
Day 0-20

Unsolicited adverse event (AE) covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade, grade 3 was unsolicited symptom that prevented normal activity and related was event assessed by the investigator as possibly related to the study vaccination.

Number of Subjects Reporting Any, Grade 3 and Related AEs With a Medically Attended Visit Between Day 0 to 20
Day 0-20

For each solicited and unsolicited AE the subject experienced, the subject was asked if they had received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as occurrence of any symptom regardless of intensity grade, grade 3 was defined as symptom that prevented normal activity and related was general symptom assessed by the investigator as possibly related to the study vaccination.

Number of Subjects Reporting Any, Grade 3 and Related AEs With a Medically Attended Visit Between Day 21 to 179
Day 21-179

For each solicited and unsolicited AE the subject experienced, the subject was asked if they had received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as occurrence of any symptom regardless of intensity grade, grade 3 was defined as symptom that prevented normal activity and related was general symptom assessed by the investigator as possibly related to the study vaccination.

Number of Subjects Reporting AEs of Specific Interest (AESI) Including Autoimmune Disease (AID)
Day 0-179

AESI for safety monitoring are a subset of AEs that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoiimune etiology. Any was defined as occurrence of any symptom regardless of intensity grade, grade 3 was defined as symptom that prevented normal activity and related was general symptom assessed by the investigator as possibly related to the study vaccination.

Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 0 to Day 20
Day 0-20

SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade and related was event assessed by the investigator as causally related to the study vaccination.

Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 21 to Day 179
Day 21-179

SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade and related was event assessed by the investigator as causally related to the study vaccination.

Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) From Day 180 to Day 209
Day 180 to Day 209

SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade and related was event assessed by the investigator as causally related to the study vaccination.

Number of Subjects Reporting Polymerase Chain Reaction (PCR)-Confirmed Influenza A and/or B Infection.
After the first dose during the corresponding surveillance period (from mid November 2008 to the end of April 2009 (end of influenza season))

Occurrence of PCR-confirmed influenza A and/or B infection, due to any matching or drift influenza strain relative to the vaccine strains (i.e. not emerging novel human influenza strain like H1N1v). PCR-confirmed influenza (PCI) was defined as an episode of influenza-like illness (ILI) occurring after the administration of the study vaccine for which a nasal and throat swab specimen yields influenza virus A and/or B by reverse transcription polymerase chain reaction (RT-PCR) analysis.

Serum Hemagglutination-inhibition (HI) Antibody Titers, Against Each of the 3 Vaccine Influenza Strains, in the FluNG Groups.
At Days 0 (pre-vaccination Dose 1) and 21 (post-vaccination Dose 1) of the first year (2008/2009) of the study

Vaccine strains assessed were A/Brisbane/59/2077, A/Uruguay/716/2007 and B/Brisbane/3/2007. Titers were expressed as geometric mean titers calculated on all subjects in the lot-to-lot subset of subjects.

Secondary Endpoints
Haemagglutination Inhibition (HI) Antibody Titers at Days 0 and 21
At Day 0 and 21
HI Antibody Titers at Day 180
Day 180
The Number of Subjects Seropositive to HI Antibodies at Day 0 and 21
At Day 0 and 21
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposePREVENTION
Treatment Arms
ArmTypeDescription
New generation influenza vaccine GSK2186877A GroupEXPERIMENTALSubjects aged ≥65 years received 1 dose of New generation influenza vaccine GSK2186877A
Fluarix elderly GroupACTIVE_COMPARATORSubjects aged ≥65 years received 1 dose of Fluarix vaccine
Fluarix young GroupACTIVE_COMPARATORSubjects aged 18-40 years received 1 dose of Fluarix vaccine
FluNG GroupEXPERIMENTALsubjects received 2 doses (1 dose per season) of FluNG vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).
Fluarix GroupACTIVE_COMPARATORsubjects received 2 doses (1 dose per season) of Fluarix™ vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).
Interventions
NameTypeDescription
GSK Bio's influenza vaccine GSK2186877ABIOLOGICALIntramuscular (IM) administration, 1 dose
FluarixBIOLOGICALIntramuscular (IM) administration, 1 dose
Fluarix TMBIOLOGICALIM administration, two times one annual dose
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersYes
Study Sites25

Inclusion Criteria: * Subjects who the investigator believes that they can and will comply with the requirements of the protocol. * A male or female aged 18-41 years or ≥65 years at the time of the vaccination and who participated in the 110847 study and completed the 6 month follow-up. * Written i...

Countries:GermanyNetherlandsSwedenUnited StatesBelgiumCanadaCzechiaEstoniaFranceMexicoNorwayPolandRomaniaRussiaTaiwanUnited Kingdom
Unlock Eligibility Criteria